ISSN:
1420-908X
Keywords:
Key words: ABT-299 — Platelet activating factor (PAF) —β-thromboglobulin — Platelet — Degranulation
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract. Objective and Design: ABT-299 is a prodrug that is converted by serum esterase to a potent platelet activating factor (PAF) antagonist (A-85783). In order to evaluate the pharmacological activity of this antagonist in man the effect of ABT-299 given to healthy volunteers on ex vivo PAF-induced β-thromboglobulin (β-TG) release in blood was assessed.¶Subjects: 37 healthy male volunteers, age 18 to 40 (mean age of 23.6 years) and free of medication, participated in the study.¶Treatment: Subjects were administered intravenously 0.8 mg, 2 mg, or 70 mg doses of ABT-299 (6–7 subjects per group) or placebo (9 subjects, pooled).¶Methods: Peripheral blood taken over 12 h after dosing was used for ex vivo β-TG release and, in the case of the 70 mg dose, measurement of plasma drug concentration. Data were compared by Student's t-test.¶Results: All three doses produced highly significant inhibition (p 〈0.005 compared to predose values) of PAF-induced β-TG release (units/ml plasma±SEM) 12 h after drug administration (54±14 vs. 405±51, n=8; 79±23 vs. 480±127, n=7; 21±10 vs. 327±72, n=6, respectively) whereas there was no significant difference in β-TG release in the placebo group (449±90 vs. 307±49, n=9). Inhibition was associated with the rapid appearance in plasma of A-85783 and the pyridine N-oxide metabolite of A-85783. Within 2 h, the plasma concentration of the metabolite exceeded that of the parent drug. Both the parent drug and the metabolite exhibited potent in vitro inhibition of PAF-induced β-TG release (A2 values of 4 and 1 nM respectively).¶Conclusions: These studies are the first to illustrate the utility of the β-TG release assay for assessing ex vivo activity of PAF antagonists. These studies also demonstrate that the administration of ABT-299 to man results in potent, long lasting inhibition of PAF-mediated platelet activation, due in part to the pyridine-N-oxide metabolite, and support the potential therapeutic utility of this prodrug in treating PAF-mediated diseases.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s000110050186
Permalink